Schroder Investment Management Group
ORKA

Schroder Investment Management Group’s Oruka Therapeutics ORKA Stock Holding History

Schroder Investment Management Group’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.33M Hold
29,184
– – ﹤0.01% 997
2025
Q4 		$850K Hold
29,184
– – ﹤0.01% 1009
2025
Q3 		$563K Buy
+29,184
New +$433K ﹤0.01% 1078

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Schroder Investment Management Group's ORKA Position: Q1 2026 in Review

Schroder Investment Management Group held its Oruka Therapeutics (ORKA) position steady in Q1 2026 at 29,184 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #997.

Schroder Investment Management Group first reported a position in ORKA in Q3 2025 and has held it in 3 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Schroder Investment Management Group held 29,184 shares of Oruka Therapeutics worth $1.33M as of Q1 2026.
  • Schroder Investment Management Group left its Oruka Therapeutics share count unchanged in Q1 2026.
  • Oruka Therapeutics made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q1 2026, its #997 holding.
  • Schroder Investment Management Group first reported a position in Oruka Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.